baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

ING Knock-Out Genmab AS/ DE000NG8L008 /

15.11.2024 16:43:08	Изменение+0.880	Бид16:54:23	Предложение16:54:23	Базовый актив	Цена исполнения	Дата истечения	Тип опциона
19.190EUR	+4.81%	- Величина цены спроса: -	- Величина цены предложения: -	-	2,886.2668 DKK	31.12.2078	Put

GlobeNewswire 30.08 HOOKIPA Pharma Announces Board of Directors Changes

GlobeNewswire 22.08 Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vacc...

GlobeNewswire 19.08 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...

GlobeNewswire 16.08 Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...

GlobeNewswire 13.08 Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08.08 Genmab Announces Financial Results for the First Half of 2024

GlobeNewswire 08.08 Genmab Updates 2024 Financial Guidance

GlobeNewswire 05.08 Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors

GlobeNewswire 05.08 BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 05.08 Genmab Takes Full Control of Acasunlimab Development Program

GlobeNewswire 30.07 BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patie...

GlobeNewswire 22.07 BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024

GlobeNewswire 28.06 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...

GlobeNewswire 27.06 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...

GlobeNewswire 24.06 BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT...

GlobeNewswire 01.06 Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...

GlobeNewswire 29.05 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

GlobeNewswire 21.05 Genmab Completes Acquisition of ProfoundBio

GlobeNewswire 21.05 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...

GlobeNewswire 17.05 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

GlobeNewswire 14.05 Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization...

GlobeNewswire 14.05 Immatics Announces First Quarter 2024 Financial Results and Business Update

GlobeNewswire 06.05 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 02.05 Genmab Announces Financial Results for the First Quarter of 2024

GlobeNewswire 30.04 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...

ING Knock-Out Genmab AS/ DE000NG8L008 /

Если вы хотите получить ответ на свой отзыв, укажите, пожалуйста, адрес своей электронной почты.